QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study

uniQure N.V. (QURE) shares surged 247.7% after its investigational gene therapy, AMT-130, met primary and key secondary endpoints in a pivotal Phase I/II study for Huntington's disease. The high-dose AMT-130 demonstrated a statistically significant 75% slowing of disease progression on cUHDRS and 60% on TFC at 36 months, along with dose-dependent functional benefits and a manageable safety profile, compared to external controls. uniQure plans to engage with the FDA this year and aims for a Biologics License Application submission in Q1 2026, leveraging AMT-130's existing FDA RMAT and Breakthrough Therapy designations, indicating a significant step toward a potential new treatment for the neurodegenerative disorder.

Analysis

uniQure N.V. (QURE) experienced a significant re-rating, with its stock surging 247.7% following the release of pivotal Phase I/II study data for its Huntington's disease gene therapy, AMT-130. The therapy met its primary endpoint, demonstrating a statistically significant 75% slowing of disease progression at 36 months as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) compared to an external control group. This was further supported by meeting a key secondary endpoint, showing a 60% slowing of progression on the Total Functional Capacity (TFC) scale. The positive results were reinforced by a favorable dose-dependent response across multiple motor and cognitive function endpoints, a reduction in the neurodegeneration biomarker neurofilament light protein by 8.2%, and a manageable safety profile with mostly mild adverse events. This successful data readout establishes a clear regulatory path forward, with uniQure planning to engage with the FDA and target a Biologics License Application submission in the first quarter of 2026, a process potentially streamlined by AMT-130's existing Breakthrough Therapy and RMAT designations.

Key Decisions for Investors

• The compelling efficacy and safety data for AMT-130 significantly de-risks uniQure's lead asset, warranting a re-evaluation of the company's fundamental value and long-term growth trajectory in the gene therapy space.
• Investors should monitor communications from the planned FDA meeting later this year and the targeted Q1 2026 BLA submission, as these regulatory milestones are the next major catalysts that will dictate the timeline to potential commercialization.
• Considering the 247.7% single-day stock appreciation, investors who held positions prior to the announcement may consider trimming a portion to realize gains, while assessing position size relative to the remaining execution risks leading up to potential approval and launch.